Modality
Bispecific Ab
MOA
HER2
Target
CD19
Pathway
Ferroptosis
IgANWilmsPancreatic Ca
Development Pipeline
Preclinical
~Apr 2015
→ ~Jul 2016
Phase 1
~Oct 2016
→ ~Jan 2018
Phase 2
~Apr 2018
→ ~Jul 2019
Phase 3
~Oct 2019
→ ~Jan 2021
NDA/BLA
Apr 2021
→ Sep 2030
NDA/BLACurrent
NCT07699376
2,744 pts·Pancreatic Ca
2021-04→2030-09·Terminated
2,744 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-124.5y awayPh3 Readout· Pancreatic Ca
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2030-09-12 · 4.5y away
Pancreatic Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07699376 | NDA/BLA | Pancreatic Ca | Terminated | 2744 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 |